logo
ScreenersREIT EarningsREIT SectorsMarketplaceLearn
Logo

Summit Therapeutics Inc.

SMMT

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials foā€¦ read more

Healthcare

Biotechnology

10 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$26.69

Price

+0.91%

$0.24

$26.45

Previous Close

$26.49

Open

Premium

52w Discount
Market Cap

$19.822b

Large

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-33.3%

3y CAGR

-40.3%

5y CAGR
Earnings

-$240.755m

-8.8%

1y CAGR

-208.4%

3y CAGR

-153.6%

5y CAGR
EPS

-$0.34

-9.7%

1y CAGR

-33.8%

3y CAGR

-10.3%

5y CAGR
Book Value

$344.330m

$383.822m

Assets

$39.492m

Liabilities

$6.450m

Debt
Debt to Assets

1.7%

-

Debt to EBITDA
Free Cash Flow

-$173.545m

-22.0%

1y CAGR

-63.1%

3y CAGR

-36.8%

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.